These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31852847)

  • 1. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming.
    Quattrocelli M; Zelikovich AS; Jiang Z; Peek CB; Demonbreun AR; Kuntz NL; Barish GD; Haldar SM; Bass J; McNally EM
    JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31852847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy.
    Quattrocelli M; Barefield DY; Warner JL; Vo AH; Hadhazy M; Earley JU; Demonbreun AR; McNally EM
    J Clin Invest; 2017 Jun; 127(6):2418-2432. PubMed ID: 28481224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program.
    Morrison-Nozik A; Anand P; Zhu H; Duan Q; Sabeh M; Prosdocimo DA; Lemieux ME; Nordsborg N; Russell AP; MacRae CA; Gerber AN; Jain MK; Haldar SM
    Proc Natl Acad Sci U S A; 2015 Dec; 112(49):E6780-9. PubMed ID: 26598680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas M; Mitchell J
    Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy.
    Quattrocelli M; Salamone IM; Page PG; Warner JL; Demonbreun AR; McNally EM
    Am J Pathol; 2017 Nov; 187(11):2520-2535. PubMed ID: 28823869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes.
    Weller C; Zschüntzsch J; Makosch G; Metselaar JM; Klinker F; Klinge L; Liebetanz D; Schmidt J
    J Neurosci Res; 2012 May; 90(5):1067-77. PubMed ID: 22253213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research.
    Muntoni F; Fisher I; Morgan JE; Abraham D
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S162-5. PubMed ID: 12206811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.
    Wuebbles RD; Sarathy A; Kornegay JN; Burkin DJ
    Dis Model Mech; 2013 Sep; 6(5):1175-84. PubMed ID: 23846963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy.
    Quattrocelli M; Zelikovich AS; Salamone IM; Fischer JA; McNally EM
    J Neuromuscul Dis; 2021; 8(1):39-52. PubMed ID: 33104035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy.
    Giovarelli M; Zecchini S; Catarinella G; Moscheni C; Sartori P; Barbieri C; Roux-Biejat P; Napoli A; Vantaggiato C; Cervia D; Perrotta C; Clementi E; Latella L; De Palma C
    Pharmacol Res; 2021 Aug; 170():105751. PubMed ID: 34197911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
    Jayash SN; Hamoudi D; Stephen LA; Argaw A; Huesa C; Joseph S; Wong SC; Frenette J; Farquharson C
    Calcif Tissue Int; 2023 Oct; 113(4):449-468. PubMed ID: 37470794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy.
    Yoon SH; Chen J; Grynpas MD; Mitchell J
    Bone; 2016 Sep; 90():168-80. PubMed ID: 27373502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx mice.
    Huynh T; Uaesoontrachoon K; Quinn JL; Tatem KS; Heier CR; Van Der Meulen JH; Yu Q; Harris M; Nolan CJ; Haegeman G; Grounds MD; Nagaraju K
    J Pathol; 2013 Oct; 231(2):223-35. PubMed ID: 23794417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing the Pathogenesis of Duchenne Muscular Dystrophy Using Mouse Models.
    Morrison-Nozik A; Haldar SM
    Methods Mol Biol; 2018; 1687():107-119. PubMed ID: 29067659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
    Cozzoli A; Rolland JF; Capogrosso RF; Sblendorio VT; Longo V; Simonetti S; Nico B; De Luca A
    Neuropathol Appl Neurobiol; 2011 Apr; 37(3):243-56. PubMed ID: 20618838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
    Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
    J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can photobiomodulation therapy be an alternative to pharmacological therapies in decreasing the progression of skeletal muscle impairments of mdx mice?
    Tomazoni SS; Casalechi HL; Ferreira CSB; Serra AJ; Dellê H; Brito RBO; de Melo BL; Vanin AA; Ribeiro NF; Pereira AL; Monteiro KKDS; Marcos RL; de Carvalho PTC; Frigo L; Leal-Junior ECP
    PLoS One; 2020; 15(8):e0236689. PubMed ID: 32785240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.